Concurrent Radiochemotherapy with Vinorelbine plus Cisplatin or Carboplatin in Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and an Increased Risk of Treatment Complications: Preliminary Results

Strahlentherapie und Onkologie

Volumn 179, Issue 12, 2003, Pages 823-831

  Semrau, Sabine ^a   Bier, Anette ^a   Thierbach, Ulrike ^b   Virchow, Christian ^a   Ketterer, Peter ^b   Fietkau, Rainer ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Klinikum Sudstadt   (Germany)

Author keywords

Carboplatin; Cisplatin; Concurrent radiochemotherapy; Non small cell lung cancer; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; ESOPHAGITIS; FEMALE; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE; MALE; PERIPHERAL NEUROPATHY; PNEUMONIA; PROGNOSIS; RADIATION DOSE; RECURRENT CANCER; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PARTICLE ACCELERATORS; RADIOGRAPHY, THORACIC; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE; WORLD HEALTH ORGANIZATION;

EID: 0344236305     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-1127-8     Document Type: Article

References (35)

1. Belani C. Combined modality therapy for unresectable stage III non-small cell lung cancer. Chest 2000;117:127S-32S.
2. Choy H, Safran H, Akerley W, et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non small cell lung cancer. Clin Cancer Res 1998;4:1931-6.
3. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000;19:abstract 484.
4. Dillman RD, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
5. Dillman RD, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-5.
6. Fietkau R. Concomitant radiochemotherapy of advanced non-small-cell lung cancer. Lung Cancer 2001;33:Suppl 1:S65-76.
7. Fietkau R, Sauer R. Die frühzeitige Radiotherapie im Rahmen der Radiochemotherapie des kleinzelligen Bronchialkarzinoms ist im Stadium "Limited Disease" der späteren Bestrahlung überlegen. Strahlenther Onkol 2002;178:585-8.
8. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
9. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13:452-8.
10. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-70.
11. Jeremic B, Shibamoto Y, Milicic B, et al. Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC): long term results of a phase II study. Int J Radiat Oncol Biol Phys 1998;42: 1091-6.
12. Jeremic B, Shibamoto Y, Milicic B, et al. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1999;44:343-8.
13. Johnson DH. Locally advanced unresectable non-small-cell lung cancer: new treatment strategies. Chest 2000;117:Suppl 1:123S-6S.
14. Kisohara A, Simizu T, Uehara N, et al. Phase II study of navelbine (NVB)-cisplatin (CDDP) combination chemotherapy with concurrent radiation in non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:abstract 2711.
15. Komaki R, Scott C, Ettinger D, et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 1997;38:149-55.
16. Lanfranco C, Testore F, Galliano M, et al. Concomitant chemoradiation therapy with carboplatin and vinorelbine in non-small-cell lung cancer (NSCLC). Low toxicity and active treatment. Presented at the 9th International Congress on Anti-Cancer Treatment (SOMPS), Paris; Feb. 2-5, 1999:150.abstract 074.
17. Lau DH, Ryu JK, Gandara DR, et al. Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study. Int J Radiat Oncol Biol Phys 1997;38:157-61.
18. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-23.
19. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992;84:58.
20. Marnitz S, Stuschke M, Bohsung J, et al. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer. Strahlenther Onkol 2002;178:651-8.
21. Movsas B, Scott C, Sause W et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999;45:1143-9.
22. Perez C, Stanley K, Rubin P, et al. A prospective randomised study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung: preliminary report by the Radiation Therapy Oncology Group. Cancer 1980;45:2744-53.
23. Rosenow EC. Lung cancer: update on screening, diagnosis, and prognosis. Consultant 1995;35:1355-71.
24. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-5.
25. Sause WT, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy OncoLogy Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-64.
26. Sause WT, Scott C, Taylor S, et al. Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer, Radiation Therapy Oncology Group 88-04. Am J Clin Oncol 1992;15:163-7.
27. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
28. Scalliet P, Goor C, Galdermans D, et al. Gemcitabine with thoracic radiotherapy - a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998;17:abstract 1923.
29. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;32:524-30.
30. Slanina J, Laubenberger J. CT-based study on potential mediastinal lymph node spread of patients with lung cancer. Contribution to 3-D treatment planning for adjuvant radiotherapy of the mediastinum. Strahlenther Onkol 2002;178:199-208.
31. Vokes EE, Herndon JE, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 2002;20:4191-8.
32. Wulf J, Hädinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001;177:645-55.
33. Zatloukal P, Petruzelka L, Zemanova M, et al. Vinorelbine plus cisplatin and concurrent radiotherapy in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1998;17:abstract 1947.
34. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study. Proc Am Soc Clin Oncol 2000;19:abstract 1976.
35. Zips D, Taha M, Platzbecker H, et al. Ösophagusverschluss 5 Monate nach Bestrahlung eines zentralen Bronchialkarzinoms. Strahlenther Onkol 2001; 177:367-70.